This article was originally published in The Rose Sheet
Executive SummaryMichael Steiger, PhD, appointed senior VP-R&D, reporting to President and Chief Operating Officer Arie Kopelman. Previously Juvena/La Prairie VP-R&D, Steiger will work with Chanel American, European and Asian teams "to leverage and translate international scientific findings into innovative products," firm says. He also will serve as key spokesman on technical issues, new product introductions and trends for Chanel beauty and fragrance brands
You may also be interested in...
CMR Surgical’s Versius robotic system is now live in the UK NHS, the company announced 20 February.
Despite seeing an 8% drop in global turnover in 2019, an upbeat Teva says the completion of its restructuring plan has positioned the company to increase its turnover through newly-launched products – including biosimilars, brands and new generics – as well as improve its profit margins through manufacturing optimization.
Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.